GENFIT (XUP.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:XUP - FR0004163111 - Common Stock
XUP.DE Key Statistics, Chart & Performance
The current stock price of XUP.DE is 3.964 EUR.
XUP.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About XUP.DE
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE FR
Employees: 169
Phone: 33320164000
GENFIT / XUP.DE FAQ
What does XUP do?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
What is the current price of XUP stock?
The current stock price of XUP.DE is 3.964 EUR. The price increased by 5.93% in the last trading session.
Does GENFIT pay dividends?
XUP.DE does not pay a dividend.
How is the ChartMill rating for GENFIT?
XUP.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for XUP stock?
GENFIT (XUP.DE) currently has 169 employees.
Who owns GENFIT?
You can find the ownership structure of GENFIT (XUP.DE) on the Ownership tab.
XUP.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XUP.DE.
XUP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE. The financial health of XUP.DE is average, but there are quite some concerns on its profitability.
XUP.DE Financial Highlights
Over the last trailing twelve months XUP.DE reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -289.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| Debt/Equity | 0.09 |
XUP.DE Forecast & Estimates
13 analysts have analysed XUP.DE and the average price target is 9.03 EUR. This implies a price increase of 127.7% is expected in the next year compared to the current price of 3.964.
For the next year, analysts expect an EPS growth of -110.7% and a revenue growth -8.28% for XUP.DE